Precision medicine in the adjuvant treatment of gastric cancer

0
0 / 5 (0 votos)

The Lancet Oncology

Fecha de publicación: 19 March 2018

DOI: https://doi.org/10.1016/S1470-2045(18)30131-1

Autores: Valentina Gambardella, Andrés Cervantes

Background: Adjuvant chemotherapy is considered the standard of care after surgical resection in patients with stage IB–III gastric cancer in most Asian countries. The benefit of adjuvant chemotherapy after surgery over surgery alone in terms of overall and disease-free survival was confirmed in an individual-patient data meta-analysis1 of 3838 patients treated in 17 randomised controlled trials.

SEGUIR LEYENDO